Therapy Areas: Vaccines
Novavax Inc's NanoFlu / NVX-CoV2373 combination vaccine showed positive immune reactions to both influenza and SARS-CoV-2
12 May 2021 -

Biotechnology company Novavax Inc (Nasdaq:NVAX ) disclosed on Tuesday that the combination vaccine made of NanoFlu / NVX-CoV2373 showed positive immune reactions to both influenza and SARS-CoV-2, with a preprint of the manuscript available at

This manuscript is entitled "Combination Respiratory Vaccine Containing Recombinant SARS-CoV-2 Spike and Quadrivalent Seasonal Influenza Hemagglutinin Nanoparticles with Matrix-M Adjuvant" and shows development of compelling responses to influenza and COVID-19 and protection against the SARS-CoV-2 virus, said the company.

The company added the data is based on a preclinical study of the combination of a quadrivalent seasonal flu vaccine (NanoFlu ) and a vaccine candidate for COVID-19 (NVX-CoV2373). The preclinical study has shown that the combination vaccine of NanoFlu and NVX-CoV2373 (qNIV / CoV2373) induces functional influenza and COVID antibodies in ferrets.

Additionally, the hamsters that received the company's NanoFlu / NVX-CoV2373 combination vaccine had elevated SARS-CoV-2 anti-S-IgG levels two weeks after the first immunization and the second dose. The immune reactions triggered by NanoFlu / NVX-CoV2373 to influenza A and B strains were comparable to immunization by NanoFlu alone.

NVX-CoV2373 is a protein-based vaccine candidate developed using the company's recombinant nanoparticle technology to generate an antigen derived from the coronavirus spike (S) protein. NVX-CoV2373 is stored at 2 ° - 8 ° C and is stable so that existing channels of the vaccine supply chain can be used for distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.

In addition, the NanoFlu is a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine manufactured by Novavax in its SF9 insect cell bazulovirus system. NanoFlu uses HA amino acid protein sequences that match the recommended HA sequences from circulating wild-type virus. NanoFlu contains its patented Matrix-M saponin-based adjuvant.